BioCryst Pharmaceuticals has won U.S. Food and Drug Administration approval for the expanded use of its Orladeyo hereditary-angioedema drug for children ages 2 through 11. BioCryst on Friday said the ...
PHILADELPHIA, PA / ACCESS Newswire / December 17, 2025 / TruMerit, a worldwide leader in international credentials evaluation to support health worker careers, and the National Association of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback